Pfizer/BioNTech vaccine - key facts

Pfizer and BioNtech announced that their coronavirus vaccine candidate showed promising results in the third phase of clinical trials. Below you can find a list of key facts about vaccine.

• Large scale trial: 43,000 participants

• Participants were applied either vaccine candidate or placebo

• Participants received two doses of vaccine

• 10% of participants who received vaccine contracted Covid-19

• 90% of participants who received vaccine contracted Covid-19

• Vaccine shows 90% efficiency in preventing Covid-19

• Companies plan to produce up to 50 million doses this year and up to 1.3 billion doses in 2021

• Pfizer and BioNTech approached US regulator for emergency approval

Release triggered a massive market reaction with DE30 jumping from 12,675 to 13,300 pts and US500 moving from 3,550 pts to a fresh, intraday all-time high near 3,650 pts. Oil and industrial metals also experienced a massive jump while gold pulled back. JPY and CHF lost ground while commodity currencies like AUD, NZD and CAD surged. A closer look at the stock market shows that stocks from the "old economy" were top gainers on the news while pandemic winners slipped. Airlines, industrial and entertainment companies rallied while techs and biotechs pulled back.

Tech stocks can be seen as losers of Pfizer/BioNTech vaccine announcement. US100 is trading 2.5% lower compared to pre-news levels. Source: xStation5